Jean-Luc Perfettini

Jean-Luc Perfettini is a Research Director at Inserm and co-director of the joint research unit UMR 1030 “Molecular Radiotherapy and Therapeutic Innovation” at Gustave Roussy since 2013. His research focuses on therapeutic innovation, with the goal of developing new strategies to improve the treatment of solid tumors.

He holds a PhD in Immunology from the University of Paris Diderot (Paris 7), obtained in 2002. He initially studied the interactions between the immune system and the intracellular bacterium Chlamydia at the Institut Pasteur. He later joined Gustave Roussy to deepen his work on cell death, senescence, and the modulation of immune responses in the context of viral infections and cancer therapies.

His team investigates the mechanisms of innate anti-tumor immunity and aims to identify novel immunological checkpoints to enhance the effectiveness of existing treatments. He also explores next-generation biotherapeutic strategies involving synthetic biology, nanomedicine, and gene therapy.

Among his key projects is the development of an innovative cell therapy based on engineered human monocytes, referred to as “Therapeutic Trojan Horses.” Supported by the Gustave Roussy Foundation, this emerging program led to the creation of the biotech startup Signadori Bio, in partnership with Sofinnova Partners, with the goal of launching the first-in-human clinical trial using this technology.

Jean-Luc Perfettini is the author of over 80 scientific publications, co-inventor of 16 patents, and founder of two biotechnology startups: Findimmune and Signadori Bio. He continues to pursue disruptive research aimed at delivering novel biotherapeutic solutions for patients with hard-to-treat solid tumors.